368 related articles for article (PubMed ID: 31502118)
1. Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
La Monica S; Minari R; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Galetti M; Digiacomo G; Riccardi F; Petronini PG; Tiseo M; Alfieri R
Target Oncol; 2019 Oct; 14(5):619-626. PubMed ID: 31502118
[TBL] [Abstract][Full Text] [Related]
2. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
3. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
4. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
5. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
[TBL] [Abstract][Full Text] [Related]
6.
Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T
Mol Cancer Ther; 2019 Jan; 18(1):112-126. PubMed ID: 30322949
[TBL] [Abstract][Full Text] [Related]
7. Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.
Solassol J; Vendrell JA; Senal R; Audran P; Leenhardt F; Quantin X
Lung Cancer; 2019 Jul; 133():45-47. PubMed ID: 31200827
[TBL] [Abstract][Full Text] [Related]
8. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.
Yang Z; Yang J; Chen Y; Shao YW; Wang X
Target Oncol; 2019 Aug; 14(4):369-374. PubMed ID: 31301016
[TBL] [Abstract][Full Text] [Related]
9. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
Minari R; Bordi P; La Monica S; Squadrilli A; Leonetti A; Bottarelli L; Azzoni C; Lagrasta CAM; Gnetti L; Campanini N; Petronini PG; Alfieri R; Tiseo M
J Thorac Oncol; 2018 Jun; 13(6):e89-e91. PubMed ID: 29596911
[No Abstract] [Full Text] [Related]
10. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Gao J; Li HR; Jin C; Jiang JH; Ding JY
Clin Transl Oncol; 2019 Oct; 21(10):1287-1301. PubMed ID: 30864018
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
[TBL] [Abstract][Full Text] [Related]
13. Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
Li S; Lin X; Sun S; Li S; Zhou C
Anticancer Drugs; 2022 Oct; 33(9):963-965. PubMed ID: 36136993
[TBL] [Abstract][Full Text] [Related]
14. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
Han R; Lu CH; Hu C; Dou YY; Kang J; Lin CY; Wu D; Jiang WL; Yin GQ; He Y
Acta Pharmacol Sin; 2024 Jun; 45(6):1264-1275. PubMed ID: 38438582
[TBL] [Abstract][Full Text] [Related]
15. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
[TBL] [Abstract][Full Text] [Related]
17. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
18. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
Lee K; Kim D; Yoon S; Lee DH; Kim SW
Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
[TBL] [Abstract][Full Text] [Related]
19. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.
Chen W; Yu D; Sun SY; Li F
Acta Biomater; 2021 Jul; 129():258-268. PubMed ID: 34048974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
